Resource Summary Report

Generated by ASWG on Aug 9, 2026

PerCP/Cyanine5.5 anti-human CD80

RRID:AB_2566490
Type: Antibody

Proper Citation

BioLegend Cat# 305231, RRID:AB_2566490

Antibody Information

URL: http://antibodyregistry.org/AB_2566490

Proper Citation: BioLegend Cat# 305231, RRID:AB_2566490

Target Antigen: CD80

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP/Cyanine5.5 anti-human CD80

Description: This monoclonal targets CD80

Target Organism: human

Clone ID: Clone 2D10

Antibody ID: AB_2566490

Vendor: BioLegend

Catalog Number: 305231

Alternative Catalog Numbers: 305232

Record Creation Time: 20250819T232709+0000

Record Last Update: 20250820T052256+0000

Ratings and Alerts

No rating or validation information has been found for PerCP/Cyanine5.5 anti-human CD80.

No alerts have been found for PerCP/Cyanine5.5 anti-human CD80.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at ASWG .

Zhai Y, et al. (2026) In vitro recapitulation of intramuscular mRNA vaccination with naive and recall antigens using a human lymphoid follicle chip platform. iScience, 29(7), 116416.

Wang H, et al. (2026) Identification and characterization of bone marrow plasma cells producing IFN-??-neutralizing autoantibodies in adult-onset immunodeficiency. Cell reports. Medicine, 7(3), 102657.

Cao D, et al. (2026) Mutant KRAS Suppresses DNA Sensing by Remodeling Membrane Tension to Clear Extracellular Tumor DNA. Cancer research, 86(14), 3394.

Gu Y, et al. (2026) Targeting cholesterol esterification sensitizes liver cancer to CD8+ T cell attack by impairing metabolic and redox resilience. Immunity, 59(7), 1948.

Quiros-Fernandez I, et al. (2024) Dual T cell receptor/chimeric antigen receptor engineered NK-92 cells targeting the HPV16 E6 oncoprotein and the tumor-associated antigen L1CAM exhibit enhanced cytotoxicity and specificity against tumor cells. Journal of medical virology, 96(5), e29630.